In accordance with the Securities Board of Nepal (SEBON) regulations, shares must be issued to the general public at a 10% discount on the institutional cut-off price. Consequently, individual investors will be able to apply for the IPO at Rs 450 per share.
IPO Offering Breakdown
The company is floating a total of 1,086,500 units of shares, which represents 20.50% of its issued capital. The allocation is divided as follows:
-
Institutional Investors (40%): 434,600 units (already issued via bidding)
-
General Public (60%): 651,900 units
Note for Retail Investors: Under the book building system rules, the general public must apply for a minimum of 50 units of shares.
Bidding and Next Steps
According to Nepal Stock Exchange (NEPSE) sources, 44 eligible institutional investors submitted letters of intent during the bidding window, which ran from July 7 to July 10, 2026. Following the successful completion of this phase, Time Pharmaceuticals will now formally apply to SEBON for final approval to open the issue to the general public.
Financial Highlights (FY 2082/83)
The company’s latest financial indicators showcase an encouraging financial position:
| Financial Metric |
Value |
| Net Worth Per Share |
Rs 167.51 |
| Earnings Per Share (EPS) |
Rs 10.23 |
| Consolidated Profit |
Rs 22.82 Crore |
Upon successful listing, the company's shares will trade under the 'Production and Processing' sector on NEPSE. Nabil Investment Banking Limited has been appointed as the issue manager for this IPO.
